Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Chris Markoch

Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead

Novo Nordisk A/S (NYSE: NVO) recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026. After initially moving higher after the news, NVO stock has drifted lower, likely due to the renewed uncertainty surrounding tariff policy affecting the entire market.

This is the latest move by Novo Nordisk to compete with Eli Lilly and Co. (NYSE: LLY) in the multi-faceted weight loss and obesity market. Earlier this year, Novo announced a partnership with Septerna Inc. (NASDAQ: SEPN) to develop novel drug treatments for obesity and type 2 diabetes.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.